Benefit of taxanes as adjuvant chemotherapy for early breast cancer
Abstract
BACKGROUND: The magnitude of the survival benefit of taxanes as adjuvant chemotherapy for early breast cancer is still unclear. A pooled analysis of Phase III trials was performed to assess the advantages that adjuvant taxane chemotherapy has over standard chemotherapy.METHODS: All Phase III trials were considered eligible. A pooled analysis was accomplished and event‐based relative risk ratios (RR) with 95% confidence intervals (95% CI) were derived. The significant differences in disease‐free survival (DFS) and overall survival (OS) were explored. Magnitude outcome measures were absolute benefits and the number of patients needed to treat. A heterogeneity test was applied as well. A sensitivity analysis in 6 subpopulations was also performed.RESULTS: Nine trials designed to assess if paclitaxel or docetaxel improve survival (15,598 patients) were gathered. One of the 9 trials did not report OS results. Significant differences in favor of taxanes were seen in DFS in the overall (RR: 0.86; 95% CI, 0.81–0.90 [P<.00001]) and lymph node‐positive population (RR: 0.84; 95% CI, 0.79–0.89 [P<.0001]), and in OS in the overall (RR: 0.87; 95% CI, 0.81–0.83 [P<.0001]) and lymph node‐positive population (RR: 0.84; 95% CI, 0.77–0.92 [P<.0001]). The absolute benefits in DFS and OS in favor of taxanes ranged from 3.3% to 4.6% and from 2.0% to 2.8%, respectively.CONCLUSIONS: Considering all the available Phase III trials, taxane‐based adjuvant chemotherapy for early breast cancer seems to add a significant benefit in both DFS and OS over standard chemotherapy. The lack of significant heterogeneity in the sensitivity analysis underscores the homogeneous effect across all trials. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 22 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology GroupAnnals of Oncology, 2005
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinomaCancer, 2005
- HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast CancerJNCI: Journal of the National Cancer Institute, 2004
- Overall Survival Is Not a Realistic End Point for Clinical Trials of New Drugs in Advanced Solid Tumors: A Critical Assessment Based on Recently Reported Phase III Trials in Colorectal and Breast CancerJournal of Clinical Oncology, 2003
- Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 2002
- Meta-analyses of randomised clinical trials in oncologyThe Lancet Oncology, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998